CO-CRYSTAL FORMS OF BARICITINIB

The present disclosure relates to baricitinib co-crystals comprising baricitinib and fumaric acid in solvated and anhydrous forms. The present disclosure is also related to processes for the preparation of the baricitinib co-crystals with fumaric acid. Further, the present disclosure also relates to...

Full description

Saved in:
Bibliographic Details
Main Author KAVURU, Padmini
Format Patent
LanguageEnglish
French
Published 09.04.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to baricitinib co-crystals comprising baricitinib and fumaric acid in solvated and anhydrous forms. The present disclosure is also related to processes for the preparation of the baricitinib co-crystals with fumaric acid. Further, the present disclosure also relates to pharmaceutical compositions comprising the baricitinib co-crystals with fumaric acid and methods for treating disease using the baricitinib cocrystals with fumaric acid. La présente invention concerne des co-cristaux de baricitinib comprenant du baricitinib et de l'acide fumarique dans des formes solvatées et anhydres. La présente invention concerne également des procédés de préparation des co-cristaux de baricitinib avec de l'acide fumarique. En outre, la présente invention concerne également des compositions pharmaceutiques comprenant les co-cristaux de baricitinib avec de l'acide fumarique et des méthodes de traitement d'une maladie faisant appel aux co-cristaux de baricitinib avec de l'acide fumarique.
Bibliography:Application Number: WO2019US54644